JAN 07, 2022 3:00 PM PST

The genetic testing company 23andMe begins phase 1 clinical trial for cancer drug

WRITTEN BY: J. Bryce Ortiz

This week, 23andMe, the consumer genetic testing giant, announced that it has begun a phase 1 clinical trial on a new cancer drug. The company is well known for its at-home personal-genomics kits. These kits allow consumers to provide saliva samples, which are then sent back to 23andMe where the saliva samples are processed, and a genetic profile is created. The company then provides a personalized genetic profile back to the consumer, which includes genetic determinants such as ancestry inference and disease risk. 

23andMe is widely popular, and according to the company’s website, more than 12 million people have utilized the kits. Now, the company has studied the data from its 12 million users to identify genetic risk factors for various diseases including certain types of cancer. The company has taken this data to identify a specific target for cancer therapeutics. Kenneth Hillan, Head of Therapeutics for 23andMe said, “Our approach to drug discovery is driven by human genetics, and we have an incredibly large database from which to select and advance genetically validated targets more efficiently, and with a potentially high probability of success, than traditional drug discovery methods.” It should be noted that approximately 80% of 23andMe’s customers consent to participate in research. The 23andMe scientists study aggregate, de-identified genetics of the customers alongside a database of more than 4 billion health survey answers.

For this particular clinical trial, 23andMe used their genetic database and identified a specific cellular pathway, called CD200R1. The company found that when there were alterations in this pathway, an individual’s predisposition for developing cancer significantly increased. Many other studies have shown that the CD200R1 pathway is involved in immune system regulation and modulates cancer cells. The company said that their drug, called 23ME-00610, has the capability to interact with the CD200R1 pathway, which may help to reinvigorate immune cells and possibly restore their ability to kill cancer cells. 

The phase 1 study will help to determine the safety and tolerability of 23ME-00610 and allow for the preliminary assessment of anticancer activity. After the phase 1 trial, future clinical trials will study the efficacy of the drug against specific cancers and determine the overall potency of the drug against cancer cells in humans. Anne Wojcicki, CEO of 23andMe, said, “when we started our Therapeutics group, our goal was to find new medicines validated by human genetics for people with serious unmet medical needs. That’s why we’re excited to move 23ME-00610 into the clinical to potential help people with cancer who are in need of new treatment options.”

 

 

Sources: 23andMe23andMe PrivacyAdvances in ImmunologyOncoImmunology

About the Author
PhD in Neuroscience
Science and medical writer | Researcher | Interested in the intersection between translational science, drug development, and policy
You May Also Like
APR 20, 2022
Microbiology
Rapid AST: A key weapon in the fight against AMR
APR 20, 2022
Rapid AST: A key weapon in the fight against AMR
Despite the dire, well-documented risks of antimicrobial resistance (AMR), which threatens to kill 10 million people a y ...
APR 21, 2022
Cannabis Sciences
One of the most lucrative skillsets in cannabis
APR 21, 2022
One of the most lucrative skillsets in cannabis
For anyone looking for a well-compensated, in demand job in the cannabis industry, you can't go wrong with becoming an e ...
APR 25, 2022
Microbiology
How a Serious Infection Can Cause Mood Disorders
APR 25, 2022
How a Serious Infection Can Cause Mood Disorders
When a pathogen invades the body, the immune system has to mount a response, which involves inflammation. But inflammati ...
MAY 11, 2022
Drug Discovery & Development
Gene Therapy Shows Promise for Neuropathic Pain
MAY 11, 2022
Gene Therapy Shows Promise for Neuropathic Pain
A gene therapy has been able to inhibit neuropathic pain with no detectable side effects in mice with spinal cord and pe ...
MAY 22, 2022
Drug Discovery & Development
Gout Medication Helps Hospitalized People with Heart Failure
MAY 22, 2022
Gout Medication Helps Hospitalized People with Heart Failure
A research team at the University of Virginia Hospital System found that a regularly-used medication for gout, called co ...
JUN 13, 2022
Microbiology
Mucus Contains Fungus-Fighting Molecules
JUN 13, 2022
Mucus Contains Fungus-Fighting Molecules
The human body plays host to a variety of microorganisms, including fungi like Candida albicans. Some strains of Candida ...
Loading Comments...